Cleavable isoforms of the ErbB4 receptor tyrosine kinase release a soluble intracellular domain (ICD) that may translocate to the nucleus and regulate signaling. However, ErbB4 gene is alternatively spliced generating CYT-1 and CYT-2 isoforms with different cytoplasmic tails. Here, we addressed whether the two alternative ErbB4 ICDs of either CYT-1 (ICD1) or CYT-2 (ICD2) type differ in signaling to the nucleus. Confocal microscopy and extraction of nuclear cell fractions indicated that significantly more ICD2 translocated to the nuclei when compared to ICD1. Unlike the membrane-anchored 80 kDa fragments derived from full-length ErbB4 isoforms, the two ICDs did not differ from each other in metabolic stability or ubiquitylation. However, ICD2 was phosphorylated at tyrosine residues to a higher extent and demonstrated greater in vitro kinase activity than ICD1. Mutating the ATP-binding site within ICD2 kinase domain (ICD2 K751R) blocked its tyrosine phosphorylation and significantly reduced its nuclear translocation. When expressed in the context of full-length ErbB4, ICD2 was also more efficient than ICD1 in promoting transcriptional activation of the STAT5 target gene b-casein. These findings indicate that the two alternative ICDs of ErbB4 differ in their nuclear accumulation, and that the mechanism involves differential kinase activity but not ubiquitin-regulated ICD stability.
Introduction
ErbB4 is a receptor tyrosine kinase that belongs to the epidermal growth factor receptor (EGFR, ErbB) family. ErbB4 regulates cardiovascular, neural and epithelial development, and has a controversial role in tumorigenesis (Yarden and Sliwkowski, 2001; Gullick, 2003; Hynes and Lane, 2005) . Upon ligand-induced dimerization, ErbB4 kinase stimulates cellular responses by phosphorylation events activating intracellular signaling cascades, such as mitogen-activated protein kinase (MAPK) or phosphoinositide 3-kinase (PI3-K)/Akt pathways. In addition, ErbB4 has recently been demonstrated to undergo regulated intramembrane proteolysis (RIP), resulting in generation of a soluble intracellular domain (ICD) (Ni et al., 2001; Lee et al., 2002) . Regulated proteolysis of ErbB4 involves two enzymes functioning in succession: First, ErbB4 ectodomain is shed at the extracellular juxtamembrane (JM) domain by a proteinase such as tumor necrosis factoralpha converting enzyme (TACE) (Vecchi et al., 1996; Elenius et al., 1997; Rio et al., 2000) . This is followed by cleavage of the remaining membrane-anchored 80 kD fragment at the transmembrane domain by g-secretase activity (Ni et al., 2001) . The released ErbB4 ICD has been suggested to translocate to the nucleus and regulate transcription (Ni et al., 2001; Komuro et al., 2003; Williams et al., 2004; Sardi et al., 2006) . Similar signaling via RIP and translocation of an ICD has been documented previously for amyloid b-protein precursor (APP) and the Notch receptors (Carpenter, 2003) .
The biological significance of the generated soluble ErbB4 ICD is currently not fully understood. ErbB4 constructs mutated at their g-secretase cleavage site or nuclear localization signal fail to activate transcription of a milk-specific b-casein gene in mammary epithelial cells (Williams et al., 2004; Vidal et al., 2005) , and ectopic ICD expression stimulates mammary epithelial cell differentiation (Muraoka-Cook et al., 2006) . ErbB4 ICD has also been reported to stimulate cell death (Ni et al., 2001 (Ni et al., , 2003 Vidal et al., 2005) , include a proapoptotic BH3 domain (Naresh et al., 2006) and to associate with Hdm2 leading to Hdm2 ubiquitylation and increase of p53 levels (Arasada and Carpenter, 2005) . However, analyses of ErbB4 isoforms (Ma¨a¨ttaë t al., 2006) or engineered mutants (Zhu et al., 2006 ) either capable or not of releasing an ICD fragment have suggested that ICD generation associates with cell proliferation and survival. In vivo, ErbB4 ICD epitope is frequently observed in the nuclei of breast cancer cells (Srinivasan et al., 2000) , and nuclear ErbB4 localization in breast cancer associates with poor survival when compared to presence of ErbB4 at the cell surface (Junttila et al., 2005) . Interestingly, interaction of ErbB4 with WW domain-containing oxidoreductase (WWOX), a tumor suppressor protein frequently deleted or downregulated in different cancer types, prevents nuclear localization of ErbB4 ICD (Aqeilan et al., 2005) .
Research on the biology of ErbB4 ICD has been complicated by the fact that the single ErbB4 gene is differentially spliced to produce four structurally and functionally different isoforms (Junttila et al., 2000; Gullick, 2003; Junttila et al., 2003) . The isoforms vary in their extracellular JM (isoforms JM-a and JM-b) or intracellular cytoplasmic (isoforms CYT-1 and CYT-2) domains. Only the JM-a isoforms with a stretch of 23 unique amino acids in the JM domain possess a cleavage site for TACE, whereas the JM-b isoforms with 13 alternative amino acids in the JM domain are proteinase resistant (Elenius et al., 1997; Rio et al., 2000; Ma¨a¨ttaë t al., 2006) . Thus, only isoforms with JM-a type of JM domain are subjected to RIP and release an ICD fragment (Ma¨a¨tta¨et al., 2006) . Two different ICDs can also be generated with either CYT-1 (ICD1) or CYT-2 (ICD2) type of an ICD (Elenius et al., 1999; Ma¨a¨ttaë t al., 2006) . The two ICDs differ in either containing (ICD1) or not (ICD2) a stretch of 16 unique amino acids (Elenius et al., 1999) . In the context of full-length ErbB4, these 16 amino acids mediate direct coupling to the PI3-K/Akt pathway (Kainulainen et al., 2000) . Here, we have addressed whether the soluble ICD1 and ICD2 differ in their intracellular targeting, stability or activity. Our findings indicate that ICD2 translocates to nucleus more efficiently than ICD1, and suggest that the mechanism involves greater tyrosine kinase activity of ICD2. These data suggest that two different signals may be generated by RIP of ErbB4 depending on the isoform of the receptor present.
Results

ErbB4 ICDs differ in subcellular localization
To analyse subcellular localization of the two variant ErbB4 ICDs, constructs encoding the sole ICDs of either CYT-1 or CYT-2 type (hereafter called ICD1 and ICD2, respectively) with or without C-terminal hemagglutinin (HA)-or Myc-tags were generated (Figure 1a ). These constructs lack coding sequences for the extracellular and transmembrane domains and thus enable comparison of functions intrinsic to ICDs and not secondary to possible differences in ligand interaction or cleavage by TACE or g-secretase. When transiently expressed in COS-7 cells and analysed by confocal microscopy both ICDs were present in cytosol and nucleus (Figure 1b) . However, the extent to which ICD2 translocated to nuclei was greater when compared to ICD1 (Figure 1b) . This was also evident in a quantitative statistical analysis of all constructs encoding similar levels of the two ICDs independent of the presence or type of the epitope tag (Figure 1c ). More efficient nuclear translocation of ICD2 than ICD1 was also observed when constructs encoding ICD1 and ICD2 with different epitope tags (ICD1-HA and ICD2-Myc) were expressed simultaneously in the same cell (Figure 1d) .
A difference between nuclear accumulation of the two soluble 80 kDa ICDs was also observed in analyses of nuclear fractions of MCF-7 breast cancer cells expressing full-length ErbB4 isoforms JM-a CYT-1 or JM-a CYT-2 (Supplementary Figure 1) . The relative difference was greater in cells in which ectopic ErbB4 expression levels were reduced as a response to extended starvation in serum-free conditions, indicating that the difference was not a direct consequence of ErbB4 protein overexpression. These findings demonstrate that the difference in nuclear localization of ICDs is also evident in the context of full-length ErbB4 receptors.
Membrane-anchored 80 kD fragments but not soluble ICDs differ in ubiquitylation and stability Differential nuclear translocation could result from different metabolic stability of the two ICDs, as previously reported for the membrane-anchored 80 kD ErbB4 fragments of CYT-1 and CYT-2 type (Ma¨a¨ttaë t al., 2006) . Different stability of the two 80 kDa membrane-anchored fragments was also observed when COS-7 cells expressing full-length ErbB4 JM-a CYT-1 or JM-a CYT-2 were analysed after enhancing 80 kDa fragment production by phorbol 13-myristate 12-acetate (PMA) and blocking protein synthesis with cycloheximide ( Figure 2a ). The degradation rates of the 80 kDa fragments derived from JM-a CYT-1 and JM-a CYT-2 differed significantly (P ¼ 0.028 for five independent experiments). In contrast, the degradation rates of the two soluble ICDs were not significantly different (P ¼ 0.72; n ¼ 5). Consistent data were obtained when half-lives of the ICD constructs were analysed by pulse-chase experiments of metabolically labeled proteins (data not shown). The 80 kDa membrane-anchored fragment derived from JM-a CYT-1 was also ubiquitylated to a greater extent than JM-a CYT-2 ( Figure 2b , lanes 1-4), suggesting that the enhanced ubiquitylation of JM-a CYT-1 associated with reduced stability of this isoform. No differences were, however, observed in the ubiquitylation between the two ICDs ( Figure 2b , lanes 5 and 6), consistent with similar stability of ICD1 and ICD2. These data demonstrate that differential nuclear localization of soluble ICD1 and ICD2 is not secondary to their different stability or ubiquitylation.
ICD2 has greater tyrosine kinase activity than ICD1 Full-length ErbB4 JM-a CYT-2 and its 80 kDa membrane-anchored fragment demonstrate more basal
Differential localization and activity of ErbB4 ICDs M Sundvall et al tyrosine phosphorylation than full-length or 80 kDa JM-a CYT-1 (Ma¨a¨tta¨et al., 2006) . To test the phosphorylation status of the soluble ErbB4 ICDs, antiphosphotyrosine western blots were carried out on anti-ErbB4 immunoprecipitates from COS-7 transfectants. As expected, more tyrosine phosphorylated 80 kDa fragment from JM-a CYT-2 was observed when compared to JM-a CYT-1 (Figure 3a , lanes 1 and 2), possibly due to enhanced stability of the CYT-2 type of 80 kDa fragment. Interestingly, the soluble ICD2 was also clearly more phosphorylated than ICD1 although both proteins were expressed in similar steady state levels ( Figure 3a , lanes 3 and 4). This difference in ICD phosphotyrosine content was at least partially due to greater autokinase activity of ICD2, as indicated by in vitro kinase assays of the same transfectants ( Figure 3b , lanes 3 and 4). However, no differences in the in vitro kinase activities were detected when equal Differential localization and activity of ErbB4 ICDs M Sundvall et al amounts of the two membrane-anchored 80 kDa isoforms were produced by PMA stimulation (Figure 3b , lanes 1 and 2). These findings indicate that the differences in kinase activities, but not in metabolic stability, of the soluble ErbB4 ICDs are associated with their differential targeting to nuclei.
Kinase activity is necessary for efficient nuclear targeting of ICD2 To more directly evaluate whether differences in kinase activity have a causal role in differential nuclear translocation of the two ICDs, the ATP-binding site within the tyrosine kinase domain of the HA-tagged ICD2 construct was mutated by changing Lys751 to Arg ( Figure 4a ). The resulting 'kinase-dead' ICD2 K751R mutant did not demonstrate autophosphorylation when analysed by antiphosphotyrosine Western blotting (Figure 4b ), consistent with a recent report of a similar ICD2 construct (Linggi et al., 2006) . Nuclear translocation of ICD2 K751R was also impaired as analysed by confocal microscopy ( Figure 4c ) and quantitation of microscopy data for statistical analysis (Figure 4d ). These findings demonstrate that kinase activity regulates nuclear targeting of ErbB4 ICD, and suggest that more ICD2 is translocated into nuclei when compared to ICD1 as a result of more efficient kinase activity of ICD2. The production of the membrane-anchored 80 kDa fragment (m80) from the fulllength receptors was stimulated by treatment with PMA 30-min before the addition of cycloheximide (left). Fraction of m80 fragments and ICDs remaining at each time point was determined by densitometry of western films from five independent experiments. P-values were determined by comparing the degradation rates of the two types of ICDs and m80s statistically using repeated measures analysis of variance. Representative western blots are also shown. (b) COS-7 transfectants expressing ErbB4 constructs and Flag-tagged ubiquitin were analysed for ErbB4 ubiquitylation by anti-ErbB4 immunoprecipitation followed by anti-Flag western blotting.
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ErbB4 CYT-2 isoform is more potent in promoting b-casein promoter activity than ErbB4 CYT-1 The observations of differential stability of the 80 kDa membrane-anchored forms and differential nuclear targeting of the soluble ICDs indicated that the ErbB4 isoforms may differ also functionally in regulating nuclear signaling events. ErbB4 ICD has previously been suggested to escort STAT5A into the nucleus and participate in transcriptional activation of the STAT5A target gene b-casein (Williams et al., 2004) . To determine whether the two ErbB4 isoforms differed in their ability to regulate nuclear STAT5 signaling when expressed as natural full-length forms, COS-7 cells transiently expressing JM-a CYT-1 and JM-a CYT-2 were analysed. Both ErbB4 isoforms coprecipitated with endogenous STAT5 (Figure 5a ) and promoted phosphorylation of Tyr 694 in STAT5A (Figure 5b ) to a similar extent. However, JM-a CYT-2 was more efficient (Po0.001 in five independent experiments) than JM-a CYT-1 in stimulating b-casein promoter activity. This was demonstrated in both COS-7 and HEK293 cell backgrounds by measuring luciferase activity after cotransfecting the cells with constructs encoding ErbB4 isoforms, STAT5A and a luciferase reporter protein downstream of b-casein promoter region (Figure 5c ). JM-a CYT-2 was still more active but the difference between the isoforms did not remain significant when cells were stimulated with neuregulin-1 (NRG-1) before luciferase assay. These findings indicate that both cytoplasmic isoforms of ErbB4 interact with and phosphorylate STAT5 but differ in their ability to promote transcriptional activity of STAT5A in the nucleus.
Discussion
ErbB4 has been demonstrated to undergo RIP generating soluble ICDs that can translocate into nucleus and regulate transcription (Ni et al., 2001; Komuro et al., 2003; Sardi et al., 2006) . However, as ErbB4 gene is alternatively spliced within its cytoplasmic domain, two structurally different ICDs (ICD1 and ICD2) can be produced by RIP (Ma¨a¨tta¨et al., 2006) . Here, subcellular localization, stability and functionality of the two ICDs were analysed. The results indicate that ICD2 is targeted more efficiently than ICD1 into the nucleus in the absence of regulation by transmembrane or ectodomain. The mechanism underlying the difference in nuclear localization may be enhanced tyrosine kinase activity of ICD2, when compared to ICD1, as impairing kinase activity suppressed nuclear accumulation of ICD2. Moreover, the differential targeting to nucleus associated with a functional difference, that is with different potency to enhance STAT5-induced b-casein promoter activity. The membrane-anchored 80 kDa fragment (m80) cleaved from ErbB4 JM-a CYT-2 has been suggested to be metabolically more stable than the membraneanchored 80 kDa JM-a CYT-1 when analysed using myeloid 32D tansfectants (Ma¨a¨tta¨et al., 2006) . In accordance, our analyses with COS-7 transfectants Figure 3 Phosphorylation and kinase activity of 80 kDa membrane-anchored fragments and ICDs. (a) COS-7 cells transiently expressing full-length isoforms JM-a CYT-1 or JM-a CYT-2 (left), or ICD1 or ICD2 (right) were analysed for ErbB4 phosphorylation by anti-ErbB4 immunoprecipitation followed by anti-phosphotyrosine western blotting. Densitometry of the western films indicated that phosphorylation of ICD2 was 12 times more efficient than phosphorylation of ICD1 (lane 4 vs 3), when the phosphotyrosine signal was normalized for total ErbB4. Similar analysis indicated no significant difference for the membrane-anchored 80 kDa fragments (lane 2 vs 1; 1.1-fold difference). (b) ErbB4 proteins expressed in COS-7 cells were analysed for in vitro kinase activity by incubating ErbB4 immunoprecipitates in the presence of ATP followed by antiphosphotyrosine western blotting. No signal was observed under similar conditions when no ATP was added (not shown). Transfectants expressing full-length receptors were stimulated for 30-min by PMA to synchronize efficient generation of the membrane-anchored 80 kDa fragments (lanes 1 and 2) . Densitometry of the western films indicated that kinase activity of ICD2 was 3.7 times more efficient as compared to ICD1 (lane 4 vs 3), when the phosphotyrosine signal was normalized for total ErbB4. Similar analysis indicated no significant difference for the PMA-generated membrane-anchored 80 kDa fragments (lane 2 vs 1; 1.2-fold difference).
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demonstrated that the membrane-anchored 80 kD fragment of CYT-2 type was more stable when compared to membrane-anchored 80 kDa CYT-1. Moreover, the membrane-anchored 80 kDa CYT-2 was ubiquitylated to a lesser extent. These findings suggest that the stretch of 16 cytoplasmic amino acids only present in CYT-1 isoform is involved in ErbB4 ubiquitylation that may regulate degradation, as well as other receptor functions such as targeting to differential cellular compartments of STAT5 signaling by ErbB4 cytoplasmic isoforms. COS-7 transiently expressing ErbB4 JM-a CYT-1 or JMa CYT-2 were assessed for association with endogenous STAT5 by coprecipitation (a) or for phosphorylation of co-transfected STAT5A by western blotting with an antibody recognizing phospho-STAT5 (b). Before lysing, cells were treated with or without 50 ng/ml of ErbB4 ligand NRG-1. (c) Cells transiently expressing ErbB4 JM-a CYT-1 or JM-a CYT-2 together with STAT5A and a reporter construct with a luciferase gene under the regulation of a b-casein promoter were stimulated with 0 or 50 ng/ ml NRG-1, and analysed for luciferase activity. The signal from five independent experiments was normalized for transfection efficiency estimated by fluorescence emitted from a cotransfected EGFP construct.
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M Sundvall et al (Marmor and Yarden, 2004; Ma¨a¨tta¨et al., 2006) . One putative binding motif residing within the CYT-1-specific sequence is a proline-rich region mediating interactions with WW domain-containing proteins (Komuro et al., 2003) . Interestingly, such WW domains are also found in ubiquitin E3 ligases containing catalytic homologous to E6-AP carboxyl terminus (HECT) domains (d'Azzo et al., 2005) . In contrast to the membrane-anchored 80 kDa fragments, no differences in ubiquitylation or stability were observed between the soluble ICD1 and ICD2. This observation suggests that ErbB4 ubiquitylation is regulated within the membrane compartment by mechanisms that are not available for ICDs released into the cytosol. Indeed, some of the HECT-type E3 ubiquitin ligases include C2 domains that convey binding of the ligases to membrane structures (d'Azzo et al., 2005) . Although no differences in the stability or ubiquitylation of the soluble ICDs were observed, ICD2 accumulated into nuclei of COS-7 transfectants more efficiently than ICD1. This led us to investigate another previously observed characteristic of the cleavable JM-a CYT-2. The 180 kDa full-length as well as the 80 kDa-cleaved membrane-anchored species of this isoform demonstrate basal ligand-independent tyrosine phosphorylation to a significantly greater extent than other ErbB4 isoforms (Ma¨a¨tta¨et al., 2006) . Indeed, ICD2 had greater phosphotyrosine content and possessed more autokinase activity than ICD1. How the 16 amino-acid difference between the cytoplasmic tails of ICD1 and ICD2 is conferred into a difference in the activity of the kinase domains remains to be elucidated. Small differences in the C-terminal tail of a tyrosine kinase protein may, however, have a significant effect on the activity of the catalytic domain. A well-characterized example is the autoinhibitory loop formed by the C terminus of c-Src that is missing from the oncogenic v-Src with greater tyrosine kinase activity and different C-terminal tail (Bjorge et al., 2000) .
A kinase-dead K751R mutant of ICD2 demonstrated less efficient nuclear accumulation when compared to wild-type ICD2, indicating a causal relationship between kinase activity and nuclear targeting. Although the molecular mechanism is not currently known, enhanced tyrosine kinase activity could affect nuclear translocation by, for example, regulating phosphotyrosine-mediated interactions of ErbB4 ICD with proteins that trap ICD into the cytosol or that control nuclear import. However, we did not observe differences between the ICDs in their effectiveness to coprecipitate with WWOX (unpublished observations), a cytosolic protein previously shown to bind ErbB4 JM-a CYT-2 into the cytosol thus preventing its nuclear translocation (Aqeilan et al., 2005) . In addition, differential coupling of the two CYT isoforms to PI3-K-dependent pathways (Kainulainen et al., 2000) did not seem to be critical as chemical inhibition of PI3-K activity did not affect differential accumulation of the two ICDs into nuclear cell fractions (Supplementary Figure 2) . Consistent with our findings, a similar kinase-dead mutant of ICD1 fused to enhanced green fluorescent protein (EGFP) has been shown to lose its ability to translocate into nuclei in mouse mammary epithelial cells (Muraoka-Cook et al., 2006) . In addition, tyrosine kinase activity has been reported to be necessary for nuclear translocation of full-length ErbB2 (Wang et al., 2004) . These findings may indicate a more general mechanism of ErbB targeting to nuclei that involves ErbB kinase activity.
Both greater stability of the membrane-anchored 80 kDa fragment of CYT-2 type, as well as the more efficient nuclear translocation of ICD2, suggested that JM-a CYT-2 could be more active in RIP-mediated signaling into the nucleus than JM-a CYT-1. One documented readout for ErbB4 activity in the nucleus is its ability to promote STAT5A-stimulated activity of b-casein promoter constructs (Williams et al., 2004) . As expected, JM-a CYT-2 was more efficient in stimulating b-casein promoter activity than JM-a CYT-1 when coexpressed in COS-7 cells together with STAT5A. This finding may provide clues to the mechanisms by which ErbB4 isoforms regulate tumorigenesis, since activation of STAT5 is associated with transformation in several cancer types (Yu and Jove, 2004) . In contrast to the transcriptional difference in b-casein promoter assays, the ErbB4 isoforms did not seem to differ in interacting with or phosphorylating STAT5. These observations suggest that the initial interaction between CYT-1 and CYT-2 and STAT5 occurs in the cytoplasm, consistent with findings that a JM-a CYT-1 construct with a mutated nuclear localization signal retains its activity to bind and phosphorylate STAT5A (Williams et al., 2004) . In addition to the b-casein promoter assays, a functional difference between the CYT isoforms in their nuclear signaling was indicated in experiments with the two ICDs fused to the DNA binding domain of the transcription factor GAL4. An ICD2-GAL4 fusion protein demonstrated weak but consistently more efficient transcriptional activity than ICD1-GAL4 (unpublished observations).
Taken together these findings demonstrate differences in the stability, ubiquitylation and kinase activity between signaling fragments generated from two different ErbB4 isoforms with alternative cytoplasmic domains. These differences may result in variable efficiency to regulate nuclear signaling events, such as to promote STAT5 activity on its target genes. These data further emphasize the rationale of analysing the biology and therapeutic applications of ErbB4 using molecular tools that differentiate between the structurally and functionally unique isoforms.
Materials and methods
Plasmid construction and transfection
Inserts encoding solely CYT-1 ICD (ICD1) or CYT-2 ICD (ICD2) with or without C-terminal HA (12CA5 epitope) or Myc (9E10 epitope) tags were generated from respective plasmids encoding full-length ErbB4 receptors, pcDNA3.1 ErbB4JM-aCYT-1 and pcDNA3.1ErbB4JM-aCYT-2 (Ma¨a¨ttaë t al., 2006), by PCR. The same 5 0 primer, TTACTTAAGC ACCATGGAAGGAAGAGCATCAAAAAGAAAAGA, was Differential localization and activity of ErbB4 ICDs M Sundvall et al used for all PCRs. The 3 0 primers were TATTATCTAGATT ACACCACAGTATTCCGGTGTCT for untagged, TATTAT CTAGATTATAAATCCTCTTCCGATATCAATTTCTGTT CCACCACAGTATTCCGGTGTCT for Myc-tagged, and TATTA TCTAGATTATGCGTAATCGGGTACATCGTAT GGGTACACCACAGTATTCCGGTGTCT for HA-tagged ICDs, respectively. The PCR products were cloned into pcDNA3.1 hygro ( þ ) vector (Invitrogen, Carlsbad, CA, USA) using AflII and XbaI sites introduced in PCR primers. The constructs were named pcDNA3.1ErbB4ICD1, pcDNA3.1ErbB4ICD1-HA and pcDNA3.1ErbB4ICD1-Myc, pcDNA3.1ErbB4ICD2, pcDNA3.1ErbB4ICD2-HA, pcDNA3.1 ErbB4ICD2-Myc, and encoded the whole ICDs starting from residue 676 (Plowman et al., 1993) . To generate full-length ErbB4 isoforms with C-terminal Myc tags, NheI fragments including the extracellular and transmembrane domains were inserted from pcDNA3.1ErbB4JM-aCYT-1 or pcDNA3.1 ErbB4JM-aCYT-2 into constructs encoding ICD1-Myc or ICD2-Myc, respectively, to generate pcDNA3.1ErbB4JM-aCYT-1-Myc and pcDNA3.1ErbB4JM-aCYT-2-Myc. The putative ATP binding site within the ErbB4 kinase domain was mutated (K751R) in pcDNA3.1ErbB4ICD2-HA using QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) to produce kinase-dead pcDNA3.1Erb-B4ICD2-HA-K751R. Plasmid expressing Flag-tagged ubiquitin has been described previously (Katz et al., 2002) .
COS-7, HEK293 and MCF-7 cells were transiently transfected with different ErbB4 constructs using FuGENE 6 transfection reagent (Roche, Indianapolis, IN, USA) according to manufacturer's instructions and analysed 24-48 h later. Before the experiments the cells were starved in serum-free conditions for 6-18 h to reduce total ErbB4 expression and enhance relative differences in nuclear ErbB4 ICD accumulation (Supplementary Figure 1) .
Confocal microscopy
Subcellular localization of ICDs with or without tags was analysed by confocal microscopy with Zeiss LSM 510 Meta equipment using a monoclonal mouse anti-Myc peptide antibody (clone 9 E10; Zymed, San Francisco, CA, USA), rat anti-HA peptide antibody (epitope 12CA5; Zymed), a mouse monoclonal anti-ErbB4 antibody (HFR-1; NeoMarkers, Fremont, CA, USA) and Alexa Fluor 488 goat antimouse and Alexa Fluor 568 goat anti-rat (Molecular Probes, La Jolla, CA, USA) as secondary antibodies. Nuclei were visualized using TO-PRO-3 nuclear stain (Molecular Probes).
Intensity of nuclear ICD staining was scored by comparing to cytosolic staining intensity in the same cell as follows: 3 þ , more signal in nucleus than in cytosol; 2 þ , equal signal in nucleus and cytosol; 1 þ , more signal in cytosol than in nucleus; À, no signal in nucleus but staining detectable in cytosol. Differences between ICD1 and ICD2 in nuclear staining intensity were compared separately for differentially tagged constructs (no tag, HA-tag, Myc-tag) using MantelHaenzel w 2 test. Each analysis included at least 50 randomly selected cells. Statistical computations were done with SAS System for Windows, release 8.02 (SAS Institute Inc., Cary, NC, USA). P-values less than 0.05 were considered statistically significant. Similar expression of the different ICD constructs was confirmed by simultaneous western analyses with antiErbB4 antibodies (sc-283; Santa Cruz, Santa Cruz, CA, USA) as described (Kainulainen et al., 2000) .
ErbB4 degradation analysis
To study the relative degradation rates of ErbB4 isoforms, COS-7 cells were transiently transfected with Myc-tagged ErbB4 constructs. Cells were starved without serum for 12 h after which ErbB4 cleavage was stimulated or not by PMA (100 ng/ml; Sigma-Aldrich, St Louis, MO, USA) for 30-min. Cells were washed with phosphate-buffered saline, and treated with protein synthesis inhibitor cycloheximide (100 mM; Sigma-Aldrich) in fresh medium without serum for different time periods. Samples of lysed cells were analysed by western blotting using an anti-ErbB4 antibody (sc-283; Santa Cruz) recognizing the C-terminal end of ErbB4, as previously described (Kainulainen et al., 2000; Ma¨a¨tta¨et al., 2006) . When lysates from cells expressing full-length receptors were analysed, X95% of ErbB4 migrating at the size of 80 kD represented cleaved membrane-anchored ErbB4 fragments (Ma¨a¨tta¨et al., 2006) . The results were quantitated using MCID M5 þ software (Imaging Research Inc., Bucks, UK). The rate of degradation of the two types of ICDs and m80s was compared statistically using repeated measures analysis of variance. The analysis was based on five independent experiments.
Analysis of ErbB4 ubiquitylation
To analyse ErbB4 ubiquitylation, COS-7 cells were transiently transfected with Myc-tagged ErbB4 constructs together with a plasmid encoding Flag-tagged ubiquitin. Cells were starved without serum for 12 h and treated with or without PMA for 30-min. Cell lysates were immunoprecipitated with a monoclonal anti-ErbB4 antibody (HFR-1), and analysed by western blotting using a monoclonal anti-Flag antibody (Sigma-Aldrich), as described (Kainulainen et al., 2000; Ma¨a¨tta¨et al., 2006) . Stripped membranes were reprobed with anti-ErbB4 antibody (sc-283).
ErbB4 phosphorylation analyses
To analyse ErbB4 tyrosine phosphorylation, COS-7 cells were transiently transfected with Myc-or HA-tagged ErbB4 constructs. Cells were starved without serum for 12 h. Cell lysates were immunoprecipitated with an anti-ErbB4 antibody (HFR-1), and analysed by Western blotting using an antiphosphotyrosine antibody (4G10; Upstate Biotech Inc., Charlottesville, VA, USA), as described (Kainulainen et al., 2000; Ma¨a¨tta¨et al., 2006) . Stripped membranes were reprobed with anti-ErbB4 antibody (sc-283).
The kinase activity of ICDs was determined by in vitro kinase assay, as previously described (Ma¨a¨tta¨et al., 2006) with the exception that the reaction time was 15-min. ErbB4 cleavage was stimulated by 100 ng/ml PMA for 30-min.
Regulation of STAT5 signaling by ErbB4 isoforms
Coprecipitation of ErbB4 isoforms with endogenous STAT5 and phosphorylation of STAT5A were analysed after transiently transfecting COS-7 cells with an empty pcDNA3.1 vector, pcDNA3.1ErbB4JM-aCYT-1 or pcDNA3.1ErbB4JM-aCYT-2. For STAT5A phosphorylation analysis, the cells were also cotransfected with pME18S-STAT5a . Before lysing the cells, they were starved in serum-free medium for 6 h and stimulated with 0 or 50 ng/ml NRG-1 (R&D, Minneapolis, MN, USA) for 15-min. Immunoprecipitation and western blot analyses were carried out as previously described (Kainulainen et al., 2000; Ma¨a¨tta¨et al., 2006) . The antibody used for ErbB4 precipitation was sc-283, and the primary antibodies used for western blotting were sc-835 (STAT5; Santa Cruz), sc-283 (ErbB4) and Phospho-STAT5 (STAT5 phosphorylated at Tyr 694; Cell Signaling, Beverly, MA, USA).
To measure b-casein promoter activity, COS-7 or HEK293 cells were plated a day before transfection on 24-well or
